CH BIOTECH SER(08037): The investment agreement has expired.
Chinese biotechnology services (08037) issued a notice on November 15, 2024, stating that the preconditions have not been met...
CH BIOTECH SER (08037) announced that as of November 15, 2024, the conditions precedent had not been met (or waived), and the contracting parties had not reached an agreement to further extend the final deadline. Therefore, the investment agreement (supplemented by such supplemental agreements) has been declared null and void. The directors believe that the failure of the investment agreement will not have a significant adverse impact on the group's business, operations, and financial condition.
As the investment agreement (supplemented by such supplemental agreements) has expired on November 15, 2024, the company will no longer send letters to shareholders regarding the investment agreement and the transactions proposed thereunder (including but not limited to investments and buyback rights) for reference.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
